BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025

2 hours ago 3

Article content


BioSyent Inc.
Consolidated Statements of Comprehensive Income

In Canadian Dollars	Q4 2025		Q4 2024		% Change		FY 2025		FY 2024		% Change
Net Revenues	9,671,923		8,796,684		10	%	43,051,983		35,030,897		23	%
Cost of Goods Sold	2,225,569		1,641,735		36	%	10,088,955		7,174,824		41	%
Gross Profit	7,446,354		7,154,949		4	%	32,963,028		27,856,073		18	%
Operating Expenses and Finance Income/Costs	4,967,966		4,904,040		1	%	20,933,016		18,073,575		16	%
Net Income Before Tax	2,478,388		2,250,909		10	%	12,030,012		9,782,498		23	%
Tax (including Deferred Tax)	486,600		637,715		-24	%	3,017,780		2,512,394		20	%
Net Income After Tax	1,991,788		1,613,194		23	%	9,012,232		7,270,104		24	%
Net Income After Tax % to Net Revenues	21	%	18	%			21	%	21	%
EBITDA¹	2,528,561		2,241,112		13	%	12,122,756		9,343,012		30	%
EBITDA¹ % to Net Revenues	26	%	25	%			28	%	27	%

Article content


BioSyent Inc.
Consolidated Statements of Financial Position

AS AT	December 31, 2025		December 31, 2024		% Change
ASSETS

Cash, cash equivalents and short-term investments	$	28,651,823	$	15,940,971	80	%
Trade and other receivables		4,456,562		2,906,829	53	%
Inventory		6,416,204		5,328,086	20	%
Prepaid expenses and deposits		187,977		201,971	-7	%
Derivative asset		–		5,790	-100	%
Loans receivable – current		80,395		87,433	-8	%
CURRENT ASSETS		39,792,961		24,471,080	63	%

Long term investments		3,293,957		10,103,571	-67	%
Loans receivable – current		61,799		141,140	-56	%
Deferred tax asset		510,932		401,166	27	%
Property and equipment		982,737		1,200,992	-18	%
Intangible assets		4,797,073		5,041,501	-5	%
TOTAL NON CURRENT ASSETS		9,646,498		16,888,370	-43	%
TOTAL ASSETS	$	49,439,459	$	41,359,450	20	%

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES	$	7,215,608	$	5,405,106	33	%
NON CURRENT LIABILITIES		758,345		951,159	-20	%
Long term debt		–		–	0	%
Total Equity		41,465,506		35,003,185	18	%
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$	49,439,459	$	41,359,450	20	%

Article content

EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

Article content

A reconciliation of EBITDA to NIAT for the three months, twelve months, and trailing twelve months ended December 31, 2025 and 2024 is provided in the table below:

Article content

		Three Months (Q4) Ended December 31				Full Year (FY) Ended December 31
		2025		2024		2025		2024
EBITDA		2,528,561		2,241,112		12,122,756		9,343,012
Add:	Interest Income	187,767		260,088		809,100		1,088,586
Less:	Depreciation – Property, Equipment	(70,964	)	(72,113	)	(272,299	)	(281,220	)
	Amortization of Intangible Assets	(155,498	)	(164,207	)	(580,192	)	(308,728	)
	Interest Expense	(11,478	)	(13,971	)	(49,353	)	(59,152	)
	Income Tax Expense	(486,600	)	(637,715	)	(3,017,780	)	(2,512,394	)
NIAT		1,991,788		1,613,194		9,012,232		7,270,104

Article content

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: [email protected]
Phone: 905-206-0013
Web: www.biosyent.com

Article content

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

Article content